Neurologische Klinik und Deutsches Schwindel- und Gleichgewichtszentrum
Klinikum der Ludwig-Maximilians-Universität München, Campus Grosshadern
Marchioninistr. 15, 81377 München

Tel. ++ 49 89 4400-73678
Fax ++ 49 89 4400-76673
michael.strupp(at)med.uni-muenchen.de

Further Information:
Arbeitsgruppe Schwindel

Arbeitsgruppe Gangstörungen

Publikationen, CV

Klinische Schwerpunkte

1. Schwindel und Gleichgewichtsstörungen: Diagnose und Therapie

2. Kleinhirnerkrankungen: Therapie

3. Augenbewegungsstörungen und Nystagmus: Diagnose und Therapie

4. Gangstörungen

5. Klinische Studien zu Schwindel, Kleinhirnerkrankungen und Nystagmus

6. Angeborene neurologische Stoffwechselerkrankungen

7. Allgemeine Neurologie

Michael Strupp, MD, FANA, FEAN

Professor of Neurology

Dept. of Neurology and German Center for Vertigo and Balance Disorders
Ludwig-Maximilians-University Hospital Munich,Campus Großhadern
Marchioninistr. 15, 81377 Munich, Germany

Tel. ++ 49 89 4400-73678
Fax ++ 49 89 4400-76673
michael.strupp(at)med.uni-muenchen.de

Further Information: Arbeitsgruppe Schwindel

Publikationen, CV

Main Clinical Topics

1. Vertigo, dizziness and balance disorders: diagnosis and treatment

2. Cerebellar disorders: Treatment

3. Eye movement disorders, including nystagmus: diagnosis and treatment

4. Gait disorders

5.Clinical trials on vestibular, ocular motor and cerebellar disorders, in particular to improve their treatment

6. Inherited neuro-metabolic disorders

7. General Neurology

Main Research Topics

Vestibular, ocular motor and cerebellar disorders

• Peripheral vestibular disorders
  • Vestibular neuritis: etiology, viral pathogenesis, and therapy; distribution of Herpes simplex virus in cranial nerve ganglia and different nuclei in the brainstem
  • Cerebellar disorders: treatment and diagnosis
  • Central compensation of unilateral peripheral vestibular lesions: role of vestibular exercises, drug therapy (aminopyridines, betahistine, acetyl-DL-leucine), and somatosensory substitution in humans and animal models
  • Genetics with genome-wide association study, pathophysiology, and etiology of vestibular disorders, such as autoimmunological mechanisms of bilateral vestibulopathy and Cogan’s syndrome.
  • Pharmacotherapy of vestibular disorders with clinical trials in Menière’s disease with betahistine, vestibular paroxysmia with carbamazepine, and BPPV with vitamin D
• Central vestibular disorders and nystagmus
  • oPharmacotherapy of nystagmus, such as downbeat and upbeat nystagmus with aminopyridines and chlorzoxazone
  • oPharmacotherapy of cerebellar disorders, such as episodic ataxia type 2 and cerebellar ataxias with aminopyridines and acetyl-DL-leucine
  • Evaluation of the mechanism of nicotine-induced nystagmus and nausea
  • oDifferential effects of walking and running in vestibular lesions
• Central ocular motor disorders
  • Development of tools to diagnose inherited metabolic disorders such as Niemann-Pick type C and Gaucher disease type 3
• Animal models and studies
  • Central compensation of acute unilateral vestibular lesions on a behavioural level and with imaging techniques (cooperation with A. Zwergal)
  • Animal studies on inherited metabolic disorders (cooperation with F. Platt, Oxford)
  • Measurements of inner ear blood flow to study the pharmacological mechanisms of betahistine and its metabolites (cooperation with M. Canis)

Selected Literature

zur Publikationsliste aus Pubmed

• Books
• Brandt T, Dieterich M, Strupp M. Vertigo – Leitsymptom Schwindel. 2nd edition, Springer Medizin, Darmstadt (2013)
• Strupp M (editor) A clinical approach to vertigo, dizziness and balance disorders. KWX communications, New Delhi (2013
• Strupp M, Kremmyda O, Brandt T. Ocular motor disorders and vertigo in clinical practice. Springer, London (2017)
• Strupp M, Cohen B, Büttner U (Editors) Basic and Clinical Aspects of Vertigo and Dizziness. Ann NY Acad Sci (2009)
• Guidelines of the German Neurological Society (Editor: Diener HC, Weimar C), 5th edition, Thieme, Stuttgart 2012:
  • Augenbewegungsstörungen inklusive Nystagmus. Straumann D, Straube A, Strupp M. In charge: D. Straumann (pp 648-655)
  • Schwindel – Diagnose. Brandt T, von Brevern M, Dieterich M, Eckhardt-Henn A, Straumann D, Strupp M, Westhofen M, Wiest, G. In charge: M. Strupp (pp 622-635)
  • Schwindel – Therapie. Brandt T, von Brevern M, Dieterich M, Eckhardt-Henn A, Straumann D, Strupp M, Westhofen M, Wiest, G. In charge: M. Strupp (pp 636-655)

Methods

1) 2- and 3-D video-oculography, scleral-coil technique, measurements of the gain of the VOR by video head impulse test

2) Motion analysis using a 3-D ultrasound system

3) Testing of otolith function with cervical and ocular vestibular evoked myogenic potentials (VEMP)

4) Posturography

5) “Neuro-orthoptic” examination techniques, e.g., scanning-laser ophthalmoscopy and subjective visual vertical

6) Animal models on acute and recurrent vestibular disorders, inherited metabolic disorders, ataxias

7) In vitro techniques:

• Patch-clamp recordings from isolated vestibular hair cells, neurons and brainstem slices
• PCR, single-cell PCR, in-situ hybridization in peripheral and central nervous structures
• Immunological techniques
• Blood-flow measurements in the inner ear (pharmacological studies with betahistine and its metabolites)

Grants

BMBF:

• Prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG)
• Betahistine in acute vestibular neuritis: effects on central compensation (BETAVEST)
• Episodic ataxia type 2: Fampridine versus acetazolamide versus placebo (EAT2TREAT)
• Vitamin D in BPPV: secondary prophylaxis (VitD@BPPV)
• Carbamazepine in vestibular paroxysmia (VesPa)
• Fampridine in cerebellar gait ataxia (FACEG)
• Acetyl-DL-Leucine in cerebellar ataxia (ALCAT)

Sensorion:
Symptomatic treatment of acute unilateral vestibulopathy with Sens-111

Novartis:
Effects of oxcarbazepine in vestibular paroxysmia

Actelion:
Diagnosis of Niemann-Pick type C by examination of the ocular motor system

Team Members

Vestibular and oculomotor system:
S. Bardins, Dipl. Ing.; O. Bayer, MD; I Berger, MD; T. Bremova, MD, PhD; K. Feil, MD; C. Frenzel, C. Fischer, MD; M. Glaser,N. Goldschagg, MD; S. Himmelein, PhD; C. Karch; O. Kremmyda, MD; PhD, N. Lehrer, I. Naumann, J. Teufel, MD

In vitro experiments:
S. Himmelein, PhD;  K. Hüfner, MD

Cooperation with

Local:

• C. Adrion, PhD
• C. Adamczyk, MD
• T. Brandt, MD
• M. Dieterich, MD
• S. Glasauer, PhD
• E. Grill, PhD
• A. Horn-Bechtler, PhD
• P- MacNeilage, PhD
• U. Mannsmann, MD, PhD
• A. Rieger, PhD
• E. Schneider, PhD
• S. Schneider, MD, PhD
• R. Schniepp, MD
• F. Schöberl, MD
• H. Straka, PhD
• J.C. Tonn, MD
• A. Zwergal, MD

National:

• M. Bertlich, MD, Göttingen
• M. von Brevern, MD, Berlin
• M. Canis, MD, Göttingen
• J. Classen, MD, Essen
• F. Ihler, MD, Göttingen
• R. Kalla, Bern
• T. Klockgether, Bonn
• T. Lempert, MD, Berlin
• D. Obrist, Bern
• H. Rambold, MD, Altötting
• L. Schölz, Tübingen
• D. Timmann-Braun, Essen
• 12 clinical study centers in Germany

International:

• Y. Agraval, Baltimore, U.S.A.
• A. Bisdorff, Esch-sur-Alzette, Luxemburg
• S. Boesch, Innsbruck, Austria
• A. Bronstein, London, U.K.
• L. Hofmeyr, Johannesburg, South Africa
• J. Jen, Los Angeles, U.S.A.
• R. Kalla, Bern, CH
• C. Kennard, Oxford, U.K
• H. Kingma, NL
• J.S. Kim, Seoul, South Korea
• J. Leigh, Cleveland, U.S.A.
• F. Platt, Oxford, UK
• J. Staab, Rochester, MN, U.S.A.
• R. Spiegel, Basel
• D. Straumann, Zurich, CH
• B.P. van de Warrenburg, Nijmegen, NL
• C.W. Yip, Singapore
• D. Zee, Baltimore, U.S.A.